



19th Oncology Update: Advances and Controversies
1/13/2023 7:10:00 AM - 1/16/2023 7:30:00 PM

Target Audience:

Specialties: Pathology/Lab Medicine, Radiation Oncology, Surgical Oncology, Other
Professions: Physician (MD or DO)

Description:

The treatment of solid tumors continues to evolve and clinicians must stay abreast of the current information and recent therapeutic advances. Many tumor types require multidisciplinary treatment; many therapies previously studied only in advanced and metastatic settings are now applied in early curative stages as well. Healthcare professionals who care for cancer patients in different stages of disease need to understand the basis for these therapies. Additionally, HCPs must apply the preclinical and clinical data supporting the development and integration of these new therapies into their clinical practice. This educational conference will interactively address current management controversies, updates, and novel therapies for multiple tumor types. It will bring together experts from multiple disciplines involved in the treatment of various solid tumors. The expected outcome is further integration of new cancer care developments into the clinical practice of surgeons, medical oncologists, radiation oncologists, and allied healthcare professionals who care for cancer patients.

Learning Objectives:

- 1 Utilize an appropriate sequence for surgical, radiation and chemotherapeutic intervention into the treatment of head & neck cancer, gastrointestinal malignancies, melanoma, lung cancer, breast cancer, gynecologic cancer, and genitourinary cancers.
- 2 Describe and apply an optimal treatment approach when given patient scenarios representing a range of disease stages, clinical presentations and comorbidities.
- 3 Incorporate preventive, screening and symptom control modalities in oncology care.
- 4 Identify patients who will appropriately benefit from novel therapies in the treatment of solid tumors.
- 5 Utilize the different surgical, radiation, and systemic treatments including immunotherapies and molecular-targeted therapies for cancers at varying stages of disease.

Accreditation:

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 31.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support Acknowledgment:

The University of Texas MD Anderson Cancer Center gratefully acknowledges the following company for providing an educational grant in support of this activity. Bristol-Myers Squibb Company.

Other Contributions/Donations:

The symposium organizing committee wishes to express appreciation to the following organizations: The Khalifa Bin Zayad Al Nahyan Foundation, Ms. Kathleen Fitzsimons Love, and Dr. John Cargile.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Eric Gagneaux	Activity Administrator	Nothing to disclose - 12/26/2022
Kimberson C Tanco, MD	CE Reviewer	Grant or research support-Pharmacann - 11/23/2022
Brian K Bednarski, MD	Co-Director, Faculty	Nothing to disclose - 12/22/2022
Merrick I Ross, MD, FACS	Course Director, Faculty	Consulting Fee-Merck Sharp & Dohme Corp. (any division) Honoraria-Merck Sharp & Dohme Corp. (any division) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division) Honoraria-Amgen Inc. - 07/12/2022
Sanjiv Agarwala, MD	Faculty	Nothing to disclose - 12/15/2022
Thomas Aloia, MD, MPH	Faculty	Nothing to disclose - 01/06/2023
Robert H.I. Andtbacka, MD, FACS, FRCSC	Faculty	Employment-Seven and Eight Biopharmaceuticals Inc. - 11/16/2022
Ana Aparicio, MD	Faculty	Honoraria-Amgen Inc. (Relationship has ended) Grant or research support-Bristol-Myers Squibb Company (Relationship has ended) Grant or research support-Sanofi US (Relationship has ended) Honoraria-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended) Honoraria-Daiichi Sankyo, Inc. (Relationship has ended) Honoraria-Janssen Biotech, Inc. (Relationship has ended) Honoraria-AstraZeneca US (Relationship has ended) - 07/20/2022
Autumn Atkinson, MD	Faculty	Nothing to disclose - 12/26/2022
Brian Badgwell, MD	Faculty	Nothing to disclose - 12/16/2022
Karl Y Bilimoria, MD	Faculty	Nothing to disclose - 10/10/2022
Thomas A Buchholz, MD	Faculty	Nothing to disclose - 10/13/2022
Matthew T Campbell, MD, MS	Faculty	Advisor-Eisai, Inc. (Relationship has ended) Advisor-EMD Serono Inc. (Relationship has ended) Advisor-Pfizer Inc. (Relationship has ended) Advisor-Genentech, Inc. (Relationship has ended) Advisor-AstraZeneca US (Relationship has ended) Consulting Fee-Exelixis (Relationship has ended) Consulting Fee-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended) Consulting Fee-Seattle Genetics, Inc. (Relationship has ended) Advisor-AXDev (Relationship has ended) Grant or research support-Exelixis Grant or research support-Pfizer Inc. Grant or research support-Janssen Biotech, Inc. Grant or research support-Aveo Grant or research support-AstraZeneca US Speakers Bureau-Bristol-Myers Squibb Company (Relationship has ended) Speakers Bureau-Roche (Relationship has ended) Speakers Bureau-Merck Sharp &

		Dohme Corp. (any division) (Relationship has ended) Speakers Bureau-Society for Immunotherapy of Cancer (Relationship has ended) - 03/23/2022
Abigail Caudle, MD, ABS	Faculty	Nothing to disclose - 10/24/2022
Edward I Chang, MD	Faculty	Consulting Fee-Baxter Healthcare Corporation (Relationship has ended) - 04/22/2022
Brian F Chapin, MD	Faculty	Consulting Fee-Jazz Pharmaceuticals (Relationship has ended) - 12/20/2022
Mariana C. Chavez MacGregor , MD, MSC, Associate Profesor	Faculty	Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech, Inc. Advisor-Genomic Health, Inc. (Relationship has ended) - 07/12/2022
Lorenzo Cohen, PhD	Faculty	Nothing to disclose - 09/15/2022
Christopher H Crane, MD	Faculty	Honoraria-Elekta - 10/15/2022
John W Davis, MD, FACS	Faculty	Advisor-Intuitive Surgical, Inc. Grant or research support-Janssen Biotech, Inc. - 01/06/2023
Jason B. Fleming, MD	Faculty	Advisor-BioPath Holdings, Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.-PanTher Therapeutic, Inc. Advisor-Candel Therapeutics, Inc Independent Contractor (included contracted research)-MyCareGorithm Advisor-Natera - 10/31/2022
Steven Frank, MD	Faculty	Consulting Fee-Boston Scientific Corporation (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-C4 Imaging Grant or research support-Eli Lilly (Relationship has ended) Grant or research support-Hitachi Medical Systems America, Inc. - 12/04/2022
Michael Frumovitz, MD	Faculty	Consulting Fee-Stryker (any division) Grant or research support-GlaxoSmithKline (Relationship has ended) Grant or research support-AkesoBio Consulting Fee-Seattle Genetics, Inc. (Relationship has ended) - 07/10/2022
Jeffrey Gershenwald, MD	Faculty	Consulting Fee-Merck Sharp & Dohme Corp. (any division) Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended) - 09/18/2022
Isabella Glitza Oliva, MD, PhD	Faculty	Consulting Fee-Novartis Pharmaceuticals Corporation Grant or research support-Bristol-Myers Squibb Company Grant or research support-Pfizer Inc. Grant or research support-Merck Sharp & Dohme Corp. (any division) - 10/01/2022
John V Heymach, MD PhD	Faculty	Advisor-AstraZeneca US (Relationship has ended) Advisor-EMD Serono Inc. (Relationship

		has ended) Advisor-Boehringer Ingelheim (Relationship has ended) Advisor-Catalyst (Relationship has ended) Advisor-Genentech, Inc. (Relationship has ended) Advisor-GlaxoSmithKline (Relationship has ended) Advisor-Lilly USA, LLC Advisor-Spectrum Pharmaceuticals, Inc. (Relationship has ended) Advisor-Sanofi US (Relationship has ended) Advisor-Takeda (Relationship has ended) Advisor-Mirati (Relationship has ended) Advisor-Bristol-Myers Squibb Company (Relationship has ended) Advisor-BrightPath Biotherapeutics (Relationship has ended) Consulting Fee-Janssen Biotech, Inc. Advisor-Nexus Health (Relationship has ended) Consulting Fee-Pneuma Respiratory, Inc. (Relationship has ended) Consulting Fee-Kairos Venture Investments (Relationship has ended) Advisor-Reflexion Consulting Fee-Chugai Biopharmaceuticals (Relationship has ended) Grant or research support-AstraZeneca US Grant or research support-Bristol-Myers Squibb Company Grant or research support-Spectrum Pharmaceuticals, Inc. Royalties or Patent Beneficiary-Spectrum Pharmaceuticals, Inc. - 01/06/2023
Wayne Hofstetter, MD	Faculty	Nothing to disclose - 10/11/2022
Kelly Hunt, MD	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Armada Health Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US Grant or research support-Lilly USA, LLC Grant or research support-Cairn Surgical Grant or research support-Lumicell - 10/09/2022
Rosa F Hwang, MD, FACS	Faculty	Grant or research support-Intuitive Surgical, Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.- Stellanova Therapeutics - 12/26/2022
Matthew H Katz, MD	Faculty	Nothing to disclose - 06/14/2022
Albert C Koong, MD, PhD	Faculty	Other: Stocks-Aravive, Inc. - 10/14/2022
Bradley C Leibovich, MD, FACS	Faculty	Stocks or stock options, excluding diversified mutual funds-Pathright Medical - 11/28/2022
Jennifer K. Litton, MD	Faculty	Honoraria-UpToDate Grant or research support-Pfizer Inc. (Relationship has ended) Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants Grant or research support-Zenith Grant or research support-AstraZeneca US Grant or research support-EMD Serono Inc. Grant or research support-GlaxoSmithKline (Relationship has ended) Grant or research support-Genentech, Inc. Speakers Bureau-Clinical Care Options Speakers Bureau-Medscape (Relationship has ended) Speakers Bureau-Physician's Education Resource (Relationship has ended) Speakers Bureau-Prime Oncology

		(Relationship has ended) Speakers Bureau-Medpage - 05/04/2022
Paul F Mansfield, MD	Faculty	Stocks or stock options, excluding diversified mutual funds-Amgen Inc. Stocks or stock options, excluding diversified mutual funds-Stryker (any division) - 12/28/2022
Jennifer McQuade, MD	Faculty	Honoraria-Merck Sharp & Dohme Corp. (any division) - 01/03/2023
Funda Meric-Bernstam, MD	Faculty	Consulting Fee-AbbVie Inc. (Relationship has ended) Consulting Fee-AstraZeneca US Consulting Fee-Biovica (Relationship has ended) Consulting Fee-Black Diamond (Relationship has ended) Consulting Fee-Debiopharm (Relationship has ended) Consulting Fee-eFFECTOR Therapeutics (Relationship has ended) Consulting Fee-Eisai, Inc. (Relationship has ended) Consulting Fee-F. Hoffmann La Roche (Relationship has ended) Consulting Fee-Infinity Pharmaceuticals (Relationship has ended) Consulting Fee-Karyopharm Therapeutics (Relationship has ended) Consulting Fee-Lengo Therapeutics (Relationship has ended) Consulting Fee-LOXO-Oncology (Relationship has ended) Consulting Fee-OnCusp Therapeutics Consulting Fee-Seattle Genetics, Inc. Consulting Fee-Silverback Therapeutics (Relationship has ended) Consulting Fee-Tallac Therapeutics (Relationship has ended) Consulting Fee-Tyra Biosciences (Relationship has ended) Consulting Fee-Xencor (Relationship has ended) Consulting Fee-Zentalis (Relationship has ended) Consulting Fee-Zymeworks Grant or research support-Aileron Therapeutics Grant or research support-AstraZeneca US Grant or research support-Bayer HealthCare Pharmaceuticals, Inc. Grant or research support-Calithera Grant or research support-CytomX Therapeutics Grant or research support-Curis Grant or research support-Daiichi Sankyo, Inc. Grant or research support-Debiopharm Grant or research support-eFFECTOR Therapeutics Grant or research support-Genentech, Inc. Grant or research support-Klus Pharma Grant or research support-Novartis Pharmaceuticals Corporation Grant or research support-Puma Pharmaceuticals Grant or research support-Taiho Oncology, Inc. Consulting Fee-GT Apeiron Consulting Fee-Menarini Consulting Fee-Ecor1 - 10/25/2022
Lavinia P Middleton, MD	Faculty	Nothing to disclose - 09/20/2022
Michael Migden, MD	Faculty	Advisor-Sanofi Genzyme Advisor-Regeneron Pharmaceuticals, Inc. Advisor-Replimune Advisor-Sun pharmaceuticals - 01/06/2023

Neema Navai, MD	Faculty	Royalties or Patent Beneficiary-Allergan, Inc. - 09/28/2022
An Ngo-Huang , DO, FAAPMR	Faculty	Nothing to disclose - 10/24/2022
Anaeze Offodile II, MD MPH	Faculty	Nothing to disclose - 11/02/2022
Oliver Peacock, MD, PhD, FRCS	Faculty	Nothing to disclose - 10/12/2022
George Perkins, MD	Faculty	Nothing to disclose - 01/06/2023
David C Rice, MD	Faculty	Consulting Fee-Intuitive Surgical, Inc. - 10/07/2022
Maria C Russell, MD	Faculty	Nothing to disclose - 11/29/2022
Aysegul Sahin, MD	Faculty	Nothing to disclose - 11/09/2022
Kathleen M Schmeler, MD	Faculty	Nothing to disclose - 12/23/2022
Charles A Staley, MD	Faculty	Nothing to disclose - 01/06/2023
Sumit K Subudhi, MD, PhD	Faculty	Nothing to disclose - 10/01/2022
Stephen G Swisher, MD	Faculty	Honoraria-AstraZeneca US (Relationship has ended) - 10/19/2022
R Houston Thompson, MD	Faculty	Nothing to disclose - 10/06/2022
Hop Sanderson Tran Cao, MD, FACS	Faculty	Nothing to disclose - 09/09/2022
Ching-Wei D Tzeng, MD	Faculty	Consulting Fee-PanTher Honoraria-Johnson & Johnson (any division) (Relationship has ended) - 10/23/2022
Jeffrey Weinberg, MD, FAANS, FACS	Faculty	Nothing to disclose - 11/11/2022
James Welsh, MD	Faculty	Nothing to disclose - 01/06/2023
Robert A. Wolff, MD, Physician	Faculty	Nothing to disclose - 10/24/2022
Rae B Reynolds, PhD, MSN, RN	Other Planning Committee Member	Nothing to disclose - 04/07/2022
Cynthia Scott, AA	Other Planning Committee Member	Nothing to disclose - 07/11/2022